SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

  

Date of report (Date of earliest event reported) July 2, 2019

 

VARIAN MEDICAL SYSTEMS, INC.
(Exact Name of Registrant as Specified in its Charter)

 

Delaware 1-7598 94-2359345

(State or Other Jurisdiction

of Incorporation)

(Commission File

Number)

(IRS Employer

 Identification No.) 

 

3100 Hansen Way, Palo Alto, CA 94304-1030
(Address of Principal Executive Offices) (Zip Code)

 

Registrant's telephone number, including area code (650) 493-4000

 

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class: Trading Symbol(s) Name of each exchange on which registered:
Common Stock, $1 par value VAR New York Stock Exchange

 

 

 

 

 

Item 8.01. Other Events .

 

Varian Medical Systems, Inc. (the “ Company ”) announced on July 1, 2019 that it had entered into a definitive agreement to acquire certain embolic bead assets from Boston Scientific Corporation for $90 million. The transaction is anticipated to close later in 2019 and is subject to Federal Trade Commission, the closing of the proposed acquisition of BTG PLC by Boston Scientific Corporation and other customary closing conditions. A copy of the press release is attached as Exhibit 99.1 .

 

Item 9.01. Financial Statements and Exhibits .

 

  (d) Exhibits .
     
    The following exhibit is being furnished, and is not deemed to be filed:

 

  99.1 Press Release dated July 1, 2019 entitled “Varian to Expand Interventional Oncology Portfolio with Purchase of Embolic Bead Assets.”

  

  2  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Varian Medical Systems, Inc.
     
  By:    /s/ John W. Kuo
  Name:    John W. Kuo
  Title: Senior Vice President, General Counsel and
    Corporate Secretary

  

Dated: July 2, 2019

 

 

 

Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Varian Medical System Charts.
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Varian Medical System Charts.